- Home
- PRE
PRE
Prenetics Global Limited
as 04-01-2025 4:00pm EST
Upcoming Earnings Alert:
Get ready for potential market movements as Prenetics Global Limited PRE prepares to release earnings report on 08 Apr 2025.
| Founded: | 2014 | Country: | Hong Kong |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $9.00 | AVG Volume (30 days): | 7.7K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.85 - $7.84 | Next Earning Date: | 04-08-2025 |
| Revenue: | $25,561,362 | Revenue Growth: | -90.86% |
| Revenue Growth (this year): | 51.43% | Revenue Growth (next year): | 131.29% |
Latest Prenetics Global Limited News
PRE Breaking Stock News: Dive into PRE Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 days ago
Prenetics’ IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market
GlobeNewswire
22 days ago
Prenetics to Participate in the 37th Annual ROTH Conference
GlobeNewswire
a month ago
Prenetics Announces Fourth Quarter and Full Year 2024 Financial Results, Provides 2025 Guidance
PR Newswire
a month ago
Prenetics Announces Fourth Quarter and Full Year 2024 Financial Results, Provides 2025 Guidance
GlobeNewswire
2 months ago
Prenetics Unveils IM8 to U.S. Consumers with Co-Founding Partner David Beckham
GlobeNewswire
3 months ago
Prenetics’ IM8 Achieves Prestigious NSF Certified for Sport® for Daily Ultimate Essentials
GlobeNewswire
3 months ago
Prenetics’ IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements
ACCESSWIRE
4 months ago
iAccess Alpha's Buyside Best Ideas Virtual Winter Conference December 10-11, 2024
Compare PRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRE Prenetics Global Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.